Track record · closed signal

Thermo Fisher Scientific Inc. (TMO) — closed signal from September 19, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 18, 2025 — +15.5% at the close.

Predicted vs. what happened

TMO price · publication thesis → realized outcomesplit-adjusted
$486.75 Published $573.94 Target $562.39 Window close $601.87 Peak
$484.27 – $487.27Entry zone — fair-value band
$486.75Published — price the day we called it
$573.94Target — the price the thesis aimed for
$601.87Peak — highest point inside the window, not a realized return
$562.39Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 34 days.

At window close
+15.5%
realized, from the publication price to the last close inside the window
Peak gain
+23.6%
peak, from the publication price — not a realized return
S&P 500, same window
+1.9%
SPY over the identical days, dividend-adjusted
Window close
$562.39
last close inside the window, ended December 18, 2025
Peak price
$601.87
peak on November 25, 2025 — not a realized return
Days to target
34

The thesis — published September 19, 2025

Predicted growth
+18%
over the measurement window
Target price
$573.94
the price the thesis aimed for
Entry zone
$484.27 – $487.27
the fair-value band we waited for
Price at publication
$486.75
published September 19, 2025
Confidence
60%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

The stock looks beaten down but starting to steady. The recent average price is improving, even though one longer-term signal is still weak. Investor mood is upbeat. News points to DNA-sequencing tools in the U.S. growing through 2033, which should help demand. A fair plan is to start near 485-488, then consider adding if it climbs past 500 and buying interest is clearly stronger than usual. Keep an eye on customer budgets and rivals.

Primary drivers

  • Price looks washed out but starting to stabilize, easing near-term pressure.
  • Expected growth in DNA-sequencing demand could lift orders over the next decade.
  • Broad product lineup across life sciences adds stability and multiple growth paths.
  • Stronger-than-usual buying would signal better odds that a rebound can continue.

How it played out

TMO: target reached in 34 days

Lyra published TMO at $486.75 on 2025-09-19 with 18% expected growth. The thesis said the stock looked beaten down but was starting to steady. It pointed to improving recent price action, upbeat investor mood, DNA-sequencing demand in the U.S. through 2033, a broad life-sciences product lineup, and the need for stronger-than-usual buying.

Inside the window, the stock reached the $573.94 target in 34 days. It later peaked at $601.87 on 2025-11-25, with a 23.6% gain. By 2025-12-18 it ended at $562.39. The thesis played out.

What happened during the window

On 2025-10-29, Thermo Fisher announced an all-cash deal to acquire Clario, a drug-trial software maker. The Financial Times reported the deal value as up to $9.4 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All TMO signals